BioAffinity Operating Cycle from 2010 to 2026
| BIAF Stock | USD 1.06 0.02 1.92% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 53.01 | Current Value 50.36 | Quarterly Volatility 1.6 K |
Check BioAffinity Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 731.3 K, Interest Expense of 79.1 K or Gross Profit of 4.1 M, as well as many indicators such as Price To Sales Ratio of 1.29, Dividend Yield of 0.0 or PTB Ratio of 4.01. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies Valuation or Volatility modules.
BioAffinity | Operating Cycle | Build AI portfolio with BioAffinity Stock |
The Operating Cycle trend for bioAffinity Technologies offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether BioAffinity Technologies is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest BioAffinity Technologies' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of bioAffinity Technologies over the last few years. It is BioAffinity Technologies' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAffinity Technologies' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
BioAffinity Operating Cycle Regression Statistics
| Arithmetic Mean | 920.14 | |
| Geometric Mean | 384.17 | |
| Coefficient Of Variation | 173.09 | |
| Mean Deviation | 989.87 | |
| Median | 465.27 | |
| Standard Deviation | 1,593 | |
| Sample Variance | 2.5M | |
| Range | 5.1K | |
| R-Value | 0.17 | |
| Mean Square Error | 2.6M | |
| R-Squared | 0.03 | |
| Significance | 0.51 | |
| Slope | 54.39 | |
| Total Sum of Squares | 40.6M |
BioAffinity Operating Cycle History
About BioAffinity Technologies Financial Statements
BioAffinity Technologies stakeholders use historical fundamental indicators, such as BioAffinity Technologies' Operating Cycle, to determine how well the company is positioned to perform in the future. Although BioAffinity Technologies investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioAffinity Technologies' assets and liabilities are reflected in the revenues and expenses on BioAffinity Technologies' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in bioAffinity Technologies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 53.01 | 50.36 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of BioAffinity Technologies Correlation against competitors. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Can Biotechnology industry sustain growth momentum? Does BioAffinity have expansion opportunities? Factors like these will boost the valuation of BioAffinity Technologies. Projected growth potential of BioAffinity fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating BioAffinity Technologies demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (13.83) | Revenue Per Share | Quarterly Revenue Growth (0.39) | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies' value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because BioAffinity Technologies' market value can be influenced by many factors that don't directly affect BioAffinity Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioAffinity Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioAffinity Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioAffinity Technologies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.